To study apolipoprotein A-II, a simple, precise, and accurate immunodiffusion assay was developed and applied in a population sample of industrial employees. Apolipoprotein A-II (A-II) did not increase with age in men (r = −0.20, n = 172), but showed a slight increase with age in women (0.1 mg/dl per yr, r = 0.20, n = 188). A-II correlated significantly with apolipoprotein A-I (A-I) (r = 0.71) and high density lipoprotein (HDL) cholesterol (men, r = 0.64; women, r = 0.49). The A-I/A-II ratio was significantly related to HDL cholesterol (men, r = 0.29; women, r = 0.44). Women on no medication (n = 92) had A-II levels similar to men (34±5 and 33±5 mg/dl, mean±SD, respectively), whereas women on oral contraceptives or estrogens had significantly higher levels (39±6 mg/dl, n = 75, P < 0.01). The plasma A-I/A-II weight ratio was 3.6±0.4 for men and 3.8±0.5 for women. In the d = 1.10-1.21 subfraction, both males and females had similar A-I, A-II, and HDL cholesterol levels (men: mean, 97, 27, and 32 mg/dl, respectively; women: mean, 104, 28, and 36 mg/dl, respectively). Women had approximately twice the amount of A-I, A-II, and HDL cholesterol than men in the d = 1.063-1.10 fraction (men: mean, 10, 2, and 10 mg/dl, respectively; women: mean, 24, 4, and 19 mg/dl, respectively). The mg/dl, mean±+SD, respectively), whereas women on oral contraceptives or estrogens had significantly higher levels (39±6 mg/dl, n = 75, P < 0.01). The plasma A-I/A-Il weight ratio was 3.6±0.4 for men and 3.8±0.5 for women. In the d = 1.10-1.21 subfraction, both males and females had similar A-I, A-II, and HDL cholesterol levels (men: mean, 97, 27, and 32 mg/dl, respectively; women: mean, 104, 28, and 36 mg/dl, respectively). Women had approximately twice the amount of A-I, A-II, and HDL cholesterol than men in the d = 1.063-1.10 fraction (men: mean, 10, 2, aind 10 mg/dl, respectively; women: mean, 24, 4, and 19 mg/dl, respectively). The A-I/A-II weight ratio in the d = 1.063-1.10 fraction (men, 5.1±0.7; women, 6.1±1.3) was significantly greater (P < 0.01) than that in the d = 1.10-1.21 fraction (men, 3.7 ±0.2; women, 3.8±0.2). Furthermore, the weight ratio of cholesterol to total apoprotein A in the d = 1.063-1.10 fraction (men, 0.75±0.09; women, 0.67±0.05) was significantly higher (P < 0.01) than that found in the d = 1.10-1.21 fraction (men, 0.26±0.04, women, 0.28 A preliminary report of part of this work was presented at the 49th Annual Scientific Meeting of the American Heart Association in Miami, Fla. and was published in abstract form in 1976. Circulation. 54 (Suppl 2): 367.
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Received for publication 21 July 1976 and in revised form 10 March 1977. ±0.05). Thus, the compositions of HDL hydrated density subclasses are significantly different from each other. These results suggest that the differences in HDL between men and women are due primarily to differences in the relative proportions of HDL subclasses rather than to the intrinsic differences in HDL structure.
INTRODUCTION
High density lipoproteins (HDL),' via their interaction with lecithin-cholesterol acyltransferase, play a central role in cholesterol transport and metabolism (1) . Most HDL molecules contain two major polypeptides, A-I and A-II (2) (3) (4) (5) . Although apolipoprotein A-I (A-I) has been shown to activate the lecithin-cholesterol acyltransferase enzyme (6) 50 ,000 rpm at 10°C for 28 h. The top 10 ml of each tube was diluted to 1.125 g/ml with 1 mM disodium EDTA, pH 7.4, and then recentrifuged at 50,000 rpm for 26 h. After removing the top one-third by tube slicing, the bottom 1.125-1.21 HDL fraction was brought to 6 M guanidine hydrochloride, and incubated at 37°C for 3 h. It was then dialyzed against a KBr solution of d = 1.21, and centrifuged at 50,000 rpm for 24 h. The resulting top fraction, containing primarily A-II and the C apoproteins, was dialyzed against 0.15 M NaCl, 1 mM disodium EDTA, pH 7.4, then delipidated with ether-ethanol (7). This delipidated preparation was chromatographed on DEAE cellulose, equilibrated with 0.03 M Tris-HCl (pH 8.0) containing 6 M urea, and was then eluted with a linear gradient of NaCl from 0 to 0.125 M NaCl (8) to yield purified A-II.
Antisera to A-II was prepared by a method similar to that previously described for A-I (9).
A-Il standards and quality control samples. A-II was prepared by centrifugation and ion-exchange chromatography as outlined above. The A-II preparation was dialyzed against 5 mM NH4HCO3, pH 8.0, and assessed for protein content by the method of Lowry et al. (10) . To assess the relationship between A-II and mass, duplicate amino acid analysis was performed on two A-II standards and the molar content of A-II was calculated on the basis of the molar content of alanine (11 Radial immunodiffusion (RID) procedure. The RID procedure for the quantitation of A-II was similar to that described for A-I (9). A given volume of plasma or plasma fraction, usually 50,l, was diluted with an equal volume of TMU and mixed. The TMU-plasma mixture was diluted with a fivefold volume of Tris-urea and incubated for a minimum of 30 min at room temperature. Agarose RID plates were prepared as previously described (13 (12, 14) . For cholesterol analysis, the coefficient of variation was <4% and accuracy was within 5% of the target value; for glyceride analysis, the coefficient of variation was <5% and accuracy was within 10%. To measure HDL cholesterol, 0.15 ml of 1 M MnCl2 and 0.12 ml of 35 mg/ml heparin (Riker Laboratories, Northridge, Calif.) were added to a 3-ml aliquot of plasma, and cholesterol determination was performed on the supernatant fraction (12) . A-I was analyzed by the RID method of Albers et al. (9) .
The cholesterol and A-I and A-II contents of various ultracentrifugal fractions were determined. To prepare these fractions, fresh plasma from three to four donors of the same sex was pooled, and 4-ml aliquots were adjusted to the nonprotein solvent density of 1.10 
RESULTS
Characterization of A-II standard. Amino acid analysis of three separate preparations of A-II were nearly identical to that published (with no detectable histidine or arginine) (11) . Furthermore, the A-II preparation migrated as a single band in SDS gel electrophoresis (18) with an apparent molecular weight of the reduced form of 8,700 (Fig. 1) . 1 Immunoassay validation. The rabbit anti-human A-II sera produced a single precipitate arc of identity between delipidated HDL (apo-HDL) and purified A-II in gel diffusion plates, but did not react with human serum albumin, apoproteins A-I, C-I, C-II, C-III, D, or the "arginine-rich peptide". The relationship between the square of the diameter of the precipitate ring and the amount of A-II was linear over the range of 0.8-7.2 mg/dl (r = 0.995+0.004, n = 36). The diameters of the precipitate rings ranged from 3.2 mm for the 0.8-mg/dl standard to a maximum of 8.5 mm for the 7.2-mg/dl standard.
Apo-A-II standards diluted in either Tris buffer, Tris-urea, or TMU plus Tris-urea gave precipitate rings of comparable diameters, indicating that neither 7.2 M urea nor 0.84 M TMU affected final precipitate ring size (Fig. 2) . When various dilutions of plasma were prepared separately in each of these diluents, only TMU plus Tris-urea gave a dilution curve parallel to the standard (Fig. 3) , whereas in Tris buffer and Tris-urea, the apparent A-II concentration increased with increasing dilution. Thus, combination of TMU and Tris-urea is a valid diluent for plasma samples.
A-II values obtained on 48 plasma samples delipidated with ether-ethanol (3:1) were slightly lower (93 ±9%) than those obtained by the standard RID method using undelipidated plasma in the presence of TMU. In an additional experiment, A-II standard was added to each of two plasma pools. Eight aliquots of each of these mixtures of plasma and A-II were delipidated. The recovery of the added A-II averaged 94±6%. Thus, taking into consideration the approximate 6% loss of A-II which occurred during delipidation, the A-II values obtained on delipidated plasma were comparable to those obtained by the TMU procedure.
The effect of freezing and thawing on the plasma A-II level by RID was also studied. Six An assessment of between-assay reproducibility was also performed by including aliquots of the three quality control pools in each assay. The means and SD of these pools were as follows: 24.8±+1.5 mg/dl, n = 32; 33.7+1.2 mg/dl, n = 25; and 40.9±1.6 mg/dl, n = 25. Hence, the between-assay coefficient of variation ranged from 4 to 6%.
A-I, A-Il, and cholesterol content in ultracentrifugal fractions. Plasma ultracentrifugal fractions from six male and six female pools were analyzed for A-I, A-II, and cholesterol (Tables I and II (Table III) . Furthermore, the A-I/A-II ratios for these HDL fractions were comparable to those obtained on the previous ultracentrifugal fractions (compare Tables I and III) . Again, the A-I/A-II ratio in the d = 1.063-1.10 fraction was significantly greater than that found in the d = 1.10-1.21 fraction for both men and women, whereas the A-I/A-II ratio in either HDL fraction was not significantly different between men and women.
Plasma A-II levels in population study subjects. For men, the frequency distribution of plasma A-II values was approximately normal but slightly positively skewed (skewness, 0.59; kurtosis, 0.68) with a mean and median of 33 mg/dl (Table IV and Fig. 4) . The 10th percentile cutpoint was 28 mg/dl and the 90th percentile was 39 mg/dl. The distribution of A-II levels for the 92 women taking no medication was approximately normal (skewness, 0.25; kurtosis, 0.02) with a mean and median of 34 mg/dl. Their nonage adjusted percentile cutpoints were similar to men (10th percentile, 25 mg/dl; and 90th percentile, 40 mg/dl). Women taking estrogen-containing medications had an A-II distribution shifted to higher values with a mean of 39 mg/dl and a 90th percentile cutpoint of 45 mg/dl. Specifically, women who had taken no medication for 2 wk before blood drawing showed a significantly lower A-II level (P < 0.001) than women taking estrogen or combination estrogen-progestational preparations. However, no difference was evident in A-Il level between the group taking estrogens alone versus those taking combination oral contraceptives. Table V presents plasma A-II levels by age decade in population study subjects. Plasma A-II did not increase with age in men (r = 0.02), but showed a slight increase with age in all women (0.1 mg/dl per yr) (r = 0.20, P < 0.003). This was restricted, however, to those taking no medication. Thus, whereas the A-II levels among women on no medication showed a significant positive correlation with age (r = 0.40, P < 0.001), among women on estrogenic hormones A-Il did not increase significantly with age (r = 0.17, P < 0.07, Table VI) .
Correlation of plasma A-II with plasma A-I and lipid (Table VI) . Plasma A-II was highly correlated with plasma A-I (r = 0.71 for men and 0.72 for all women), and HDL cholesterol (r = 0.64 for men and 0.49 for all women). The A-II HDL cholesterol correlation was stronger for women on hormones (r = 0.56) than for those on no medication (r = 0.39). A-I was highly correlated with HDL cholesterol for all four groups examined (r = 0.78-0.72). A-II was only weakly correlated with total cholesterol in both men and women (r = 0.26 for men, and 0.32 for all women). However, A-II was not correlated with non-HDL cholesterol (total cholesterol minus HDL cholesterol). A-II did not correlate with log triglyceride in men but was significantly related to triglyceride in women (r = 0.36, P < 0.001). The A-I/A-II weight ratio was (25) and agrees well with the ratio of A-I to A-II obtained by column chromatography (3, 4, 26) . All the above results, however, differ from the 1:1 molar ratio obtained by electroimmunoassay (19) . It has been reported that the molar ratio ofA-I and A-II is the same for the two major HDL subclasses, i.e., HDL2 and HDL3 (24) . We found that the molar ratio of A-I to A-II in the d = 1.063-1.10 fraction (3.2 ±0.4 for men, 3.8±0.8 for women) was significantly higher than that for the d = 1.10-1.21 fraction (2.2 ±0.1 for men, and 2.3±0.1 for women). The content of cholesterol in association with the total A protein in the lighter HDL density subclass was more than double that in the heavier density subclass. Furthermore, the ratio of A-I to A-Il was positively correlated with HDL cholesterol levels. These results suggest that the major structural differences between the HDL hydrated density subclasses relate to the relative proportions of A-I and A-II. Since the composition of the HDL subclasses did not differ significantly between men and women, the differences observed in HDL composition between men and women, e.g., women's total HDL have higher cholesterol to protein ratio and higher A-I to A-Il ratio, primarily reflect the differences in the relative amounts of the HDL subclasses rather than differences in HDL structure. It should be emphasized that our HDL subclasses as isolated in the angle rotor are operational definitions and do not directly correspond to the F1.20 3.5-9 and F1.20 0-3.5 HDL subclasses as defined by the analytical ultracentrifuge (27) . Since the HDL subclasses, as used in this study, exhibit hydrated density and size heterogeneity, it is reasonable to expect that additional HDL compositional subclasses are present within each hydrated density subclass.
We report tentative age-and sex-related normal values for plasma A-Il levels. As one would predict from the close relationship found between A-I and A-II, like A-I, A-II did not increase with age in men, but showed a slight increase with age in women. The observation that women taking estrogens alone had higher A-Il, A-I, and HDL cholesterol levels than women on no medication suggests that exogenous estrogens increase HDL levels. On the other hand, women on combination estrogen-progestational preparations had comparable HDL cholesterol, somewhat higher A-I, and significantly higher A-II than women on no medication. This suggests that the progestational components of the combination oral contraceptives modify the composition of the HDL, thus altering the estrogen-promoted HDL changes. Additional studies will be required to clarify the specific hormonal effects on whole HDL and, especially, HDL subclasses.
If as suggested, HDL facilitates the clearance of cholesterol from the arterial wall (28) and modulates the transendothelial transport of low density lipoprotein (29, 30) , then high HDL levels or HDL compositional changes which increase HDL cholesterolbinding capacity may be protective against the progression of atherosclerosis. Recent epidemiological data have indicated an inverse relationship between HDL cholesterol levels and the prevalence of coronary heart disease (31). An above-average life expectancy was demonstrated for subjects with high levels of HDL cholesterol (32) . Furthermore, women have lower risk for coronary disease and higher A-I to A-II ratios than men. Since A-I/A-II ratios are positively correlated with HDL cholesterol, factors which raise 
